Study guide
18.2 DMARDs, Biologics & Their Toxicities
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
18.2 DMARDs, Biologics & Their Toxicities
Key Takeaways Explain This Topic AI
Methotrexate is given weekly with folic acid; co-prescription with trimethoprim or co-trimoxazole can cause fatal pancytopenia.
All patients must be screened for latent tuberculosis and hepatitis B before starting a TNF inhibitor, which can reactivate both.
Hydroxychloroquine requires baseline and annual retinopathy screening; sulfasalazine causes reversible oligospermia and orange discolouration of body fluids.
Last updated: September 2026
5. RA Pharmacotherapy: csDMARDs, Biologics & Crucial Toxicities
Modern UK (NICE NG100) guidelines mandate a "treat-to-target" strategy, initiating conventional synthetic DMARD (csDMARD) monotherapy or step-up combination therapy immediately upon diagnosis to arrest joint erosion. Stepwise Pharmacotherapy in Rheumatoid Arthritis
- |
- +-----------------------------------+-----------------------------------+
- | |
- 1. First-Line csDMARD 2. Biologic / tsDMARD
- Methotrexate (once weekly) - Criteria: DAS28 > 5.1
- + Folic Acid (5 mg weekly) despite >= 2 csDMARDs
- Alternatives: Sulfasalazine, - First-Line: Anti-TNF
- Leflunomide, Hydroxychloroquine (Adalimumab, Infliximab)
- Screening: Latent TB (IGRA)
- and Hepatitis B/C
- Alternatives: Rituximab,
- Tocilizumab, JAK inhibitors
- Conventional Synthetic DMARDs (csDMARDs)
Methotrexate (MTX): The gold-standard anchor csDMARD. Inhibits dihydrofolate reductase (DHFR) and aminoimidazole carboxamide ribonucleotide (AICAR) transformylase, promoting intracellular accumulation of adenosine, a potent endogenous anti-inflammatory mediator.
Dosing Safety: Must be prescribed ONCE WEEKLY (never daily; accidental daily dosing causes fatal bone marrow aplasia and mucositis).
Co-Prescription: Prescribe with folic acid (e.g. 5 mg once weekly) , taken on a day other than the methotrexate dose, to minimize gastrointestinal upset, stomatitis, and transaminitis.
Toxicities: Myelosuppression (leukopenia, thrombocytopenia), hepatotoxicity (transaminitis, hepatic fibrosis; monitored with LFTs), acute hypersensitivity pneumonitis (dry cough, dyspnoea, fever, bilateral diffuse ground-glass infiltrates; requires immediate permanent discontinuation), stomatitis, and teratogenicity (must be discontinued >= 3 months prior to planned conception in women and men).
Critical Drug Interactions:
Co-trimoxazole / Trimethoprim: Concomitant use precipitates fatal bone marrow aplasia and pancytopenia through dual mechanisms—synergistic inhibition of the folate biosynthetic pathway and competitive displacement/inhibition of renal tubular excretion of methotrexate.
NSAIDs & Aspirin: High-dose NSAIDs inhibit renal prostaglandin-mediated perfusion and compete for renal organic anion transporters, reducing methotrexate excretion and raising serum levels.
Leflunomide: Inhibits dihydroorotate dehydrogenase (DHODH) , blocking de novo pyrimidine synthesis in proliferating activated lymphocytes. Adverse effects include hepatotoxicity, hypertension, diarrhoea, peripheral neuropathy, and teratogenicity. Has an exceptionally long enterohepatic circulation half-life (~2 weeks); in acute toxicity or pregnancy planning, accelerated drug elimination via cholestyramine washout (8 g three times daily for 11 days) is required.
Sulfasalazine: Cleaved by colonic bacterial azoreductases into 5-aminosalicylic acid (5-ASA) and sulfapyridine (the active moiety in RA). Adverse effects include reversible male oligospermia, agranulocytosis, haemolysis in G6PD deficiency, and bright yellow/orange discoloration of urine and contact lenses. It is considered safe during pregnancy.
Hydroxychloroquine: Antimalarial that inhibits lysosomal acidification and toll-like receptor signaling in antigen-presenting cells. Does not cause myelosuppression or hepatotoxicity, making it an excellent combination agent. Toxicity: Retinal toxicity with irreversible macular depigmentation ( "bull's-eye" maculopathy ). UK guidelines mandate a baseline ophthalmological examination (optical coherence tomography [OCT] and fundus autofluorescence) within 12 months of initiation and annual screening after 5 years of continuous therapy. Safe in pregnancy.
Biologic DMARDs (bDMARDs) & Targeted Synthetic DMARDs (tsDMARDs)
Indicated under NICE criteria for patients with severe active disease ( DAS28 > 5.1 ) despite an adequate trial of at least two csDMARDs (including methotrexate at optimal dose):
TNF-α Inhibitors: Infliximab (chimeric IgG1 mAb), adalimumab (recombinant human mAb), certolizumab pegol (pegylated Fab fragment; does not cross placenta, safe throughout pregnancy), golimumab, and etanercept (soluble recombinant TNF receptor-Fc fusion protein).
Mandatory Pre-Treatment Screening: TNF-α is crucial for phagosomal maturation and granuloma maintenance within macrophages. Anti-TNF agents cause rapid dissolution of tuberculous granulomas; therefore, screening for latent tuberculosis with an Interferon-Gamma Release Assay (IGRA / QuantiFERON) and a plain chest radiograph is mandatory before therapy. Positive latent TB mandates chemoprophylaxis (e.g. 3 months of rifampicin/isoniazid) before biologic initiation. Screening for Hepatitis B and C is also required.
Contraindications: Active serious infection, moderate-to-severe congestive heart failure (NYHA Class III/IV), demyelinating disease (multiple sclerosis, optic neuritis).
Anti-CD20 Monoclonal Antibody (Rituximab): B-cell depleting antibody indicated for severe active seropositive RA refractory to anti-TNF agents. Administered as two 1,000 mg intravenous infusions two weeks apart. Hepatitis B serology must be checked prior to initiation due to risk of fatal fulminant hepatic reactivation.
Anti-IL-6 Receptor Antagonists (Tocilizumab, Sarilumab): Directly block IL-6 signaling. Key clinical pearl: Tocilizumab directly suppresses hepatic CRP synthesis; CRP levels remain falsely normal or near-zero even during life-threatening bacterial infections or acute gastrointestinal perforation (increased risk of lower bowel perforation in patients with diverticular disease).
Janus Kinase (JAK) Inhibitors (tsDMARDs): Oral small molecules (tofacitinib, baricitinib, upadacitinib, filgotinib) targeting JAK1/JAK2/JAK3/TYK2 signaling. Carries increased risk of herpes zoster reactivation (shingles prophylaxis recommended). MHRA and EMA safety alerts highlight an increased risk of venous thromboembolism (DVT/PE), major adverse cardiovascular events (MACE), and malignancy in patients >= 65 years, active smokers, or those with cardiovascular risk factors.
Biologic and Targeted Synthetic Classes
Class Examples Distinguishing point
TNF inhibitors Infliximab, adalimumab, etanercept, golimumab, certolizumab Reactivate latent tuberculosis and hepatitis B; etanercept is a receptor fusion protein and is the least effective in granulomatous disease
Anti-CD20 Rituximab Depletes B cells; causes hypogammaglobulinaemia and late-onset neutropenia; screen for hepatitis B
IL-6 receptor blockade Tocilizumab, sarilumab Suppresses CRP, so CRP becomes useless as an infection marker ; risk of lower gastrointestinal perforation, especially with diverticular disease
T-cell co-stimulation blockade Abatacept Lower infection risk profile
JAK inhibitors (targeted synthetic) Baricitinib, tofacitinib, upadacitinib Venous thromboembolism, herpes zoster, and increased major cardiovascular events and malignancy in older smokers
IL-17 / IL-23 Secukinumab, ustekinumab, guselkumab Used in psoriatic disease; IL-17 agents can worsen inflammatory bowel disease
The single most examinable safety point across the group is screening before initiation : latent tuberculosis (interferon-gamma release assay or tuberculin test plus chest radiograph), hepatitis B and C, HIV, and varicella immunity.
Vaccination and Pregnancy
Live vaccines are contraindicated in patients on biologics or on significant immunosuppression — this includes yellow fever, live shingles vaccine, MMR and BCG. Inactivated influenza, pneumococcal and COVID-19 vaccines are recommended, ideally two weeks before starting therapy.
In pregnancy the rules are specific and frequently tested:
Methotrexate and leflunomide are teratogenic and absolutely contraindicated. Methotrexate should be stopped at least three months before conception in both women and men; leflunomide requires a cholestyramine washout because of its very long half-life.
Hydroxychloroquine, sulfasalazine (with folic acid) and azathioprine are the DMARDs generally continued in pregnancy.
Mycophenolate mofetil is teratogenic and must be switched, usually to azathioprine, before conception.
Cyclophosphamide causes premature ovarian failure and infertility ; fertility preservation should be discussed before use in young patients.
Corticosteroid Stewardship
Corticosteroids remain a bridging therapy, not a maintenance strategy. Any patient expected to receive prednisolone 7.5 mg daily or more for three months or longer needs bone protection assessment, and prolonged therapy requires gastroprotection where NSAIDs are co-prescribed, glycaemic monitoring, and clear sick-day rules against adrenal crisis.